The Latest Cardiac and Vascular News
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C Achieved THOUSAND OAKS, Calif., March…
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation alone Late breaking findings presented at ACC.26 and simultaneously published…
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER,BC, March 27, 2026 /PRNewswire/ — USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while…
DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in advanced cardiovascular imaging analysis, will be attending the 75th Annual Scientific Session & Expo of the American College of Cardiology (ACC.26). The conference will take place March 28–30, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. ACC.26 convenes clinicians, researchers, and innovators from around the world to advance the science and practice of heart care. Cleerly will mark the conference with the launch of
The partnership will provide America’s largest independent cardiovascular practice with access to AISAP’s AI-enabled cardiac diagnostic platform NEW YORK and PHILADELPHIA, March 25, 2026 /PRNewswire/ — AISAP, a pioneer in AI-powered medical diagnostics, and Cardiology Consultants of…
March 25, 2026
BETHESDA, Md.–(BUSINESS WIRE)–CorVista Health today announced the upcoming poster presentation of new data on its non-invasive point of care test for ischemia with non-obstructive coronary arteries (INOCA) – a common condition, particularly in women, where patients experience cardiovascular symptoms despite having no flow-limiting blockages in their major epicardial arteries – using machine learning at the American College of Cardiology’s Annual Scientific Session (ACC.26), taking place March
By simplifying complex cardiac anatomy through real-time AI labeling, T-Mode™ Heart removes the training barrier to ultrasound adoption for family physicians and medical students. VANCOUVER, BC, March 23, 2026 /PRNewswire/ — With cardiovascular disease remaining a leading cause of death…
SAN FRANCISCO–(BUSINESS WIRE)– #ai–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that three abstracts featuring Viz HCM, the company’s AI-powered ECG analysis and care coordination solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), part of the Viz Cardio Suite, have been accepted for presentation at the American College of Cardiology’s Annual Scientific Session (ACC.26), taking place March 28–30,
PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that long-term efficacy and safety data in patients with ATTR-CM from the open-label extension (OLE) trial of ATTRibute-CM, its Phase 3 study of acoramidis, will be shared in a late-breaking oral presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in New Orleans, Louisiana on March 28-30, 2026. Additionally, BridgeBio was selected to share three posters on additional OLE data and real-world survey findings. Late-Breaking Oral Presentation:Long-Term Survival Benefits and Disease Stabilization with Acoramidis in Patients with ATTR-CMPresenter: Prem Soman, M.D., Ph.D., University of Pittsburgh School of MedicineDate: Monday, March 30 at 2:33 pm CT Posters:Long-Term Benefits With Acoramidis on Serum Transthyretin Concentrations and Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) Score in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Presenter: Sarah Cuddy, M.D., Brigham and Women’s HospitalDate: Saturday, March 28 at 12:30 pm CT Association Between Early Increase in sTTR with Acoramidis and Long-term Effects on Heart Failure – Related Health Status in ATTR-CM: Results from ATTRibute-CM Presenter: Jan Griffin, M.D., Medical University of South CarolinaDate: Saturday, March 28 at 3:30 pm CT Treatment Patterns and Preferences in ATTR-CM in the United States: Results from a Real-World Survey Presenter: Jill Waldron, MSN, GNP, MS, University of UtahDate: Monday, March 30 at 9:30 am CT About Attruby™ (acoramidis)INDICATIONAttruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. IMPORTANT SAFETY INFORMATIONAdverse ReactionsDiarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively). About BridgeBioBridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok. BridgeBio Media Contact:Bubba Murarka, Executive Vice Presidentcontact@bridgebio.com(650)-789-8220 BridgeBio Investor Contact:Chinmay Shukla, Senior Vice President, Strategic Financeir@bridgebio.com
